开放与机器人辅助根治性前列腺切除术并发症及与术后阿片类药物使用的关联:PREVENTER试验数据分析
基于PREVENTER试验的前瞻性队列纳入500例根治性前列腺切除术患者,比较开放与机器人辅助手术的并发症,并分析并发症与阿片类药物使用的关系。结果显示两种术式并发症无差异,盆腔淋巴结清扫和pT3b期是并发症预测因素,并发症与更高阿片类药物使用独立相关。
要点
- 开放与机器人辅助前列腺切除术的总体和主要并发症率无差异。
- 盆腔淋巴结清扫和pT3b期是并发症的独立预测因素。
- 发生并发症的患者住院和出院后阿片类药物使用量更高。
核心结论
- 开放与机器人辅助根治性前列腺切除术的总体和主要并发症率无差异,并发症与更高的术后阿片类药物使用独立相关。
研究设计与样本
- 前瞻性队列研究,纳入500例行开放或机器人辅助根治性前列腺切除术的患者,随访30天,使用Clavien-Dindo系统分类并发症。
主要发现
- 124例(24.8%)行开放手术,376例(75.2%)行机器人辅助手术,418例(83.6%)接受盆腔淋巴结清扫。
- 83例(16.6%)发生并发症,仅19例(3.8%)为主要并发症(Clavien-Dindo分级≥III),两种术式无差异。
- 盆腔淋巴结清扫(OR 2.96,95%CI 1.25-8.71;P=0.03)和pT3b期(OR 2.76,95%CI 1.23-6.00;P=0.01)是并发症的预测因素。
- 并发症患者住院阿片类药物使用更多(P=0.02),出院后使用更多(P=0.005),校正后仍显著(住院β:77.2,95%CI 17.9-136.5,P=0.03;出院β:21.9,95%CI 4.7-39.1,P=0.01)。
临床怎么用
- 对于接受盆腔淋巴结清扫或pT3b期患者,应加强并发症监测和预防。
- 并发症发生与术后阿片类药物使用增加相关,应优化疼痛管理和阿片类药物处方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate perioperative complications for open radical prostatectomy (ORP) and robot-assisted RP (RARP) for patients enrolled in the PREvention of VENous ThromboEmbolism Following Radical Prostatectomy (PREVENTER; ClinicalTrials.gov Identifier: NCT03006562) trial, to determine predictors and impact on opioid consumption. PATIENTS AND METHODS: A prospective cohort of 500 patients undergoing ORP and RARP was followed to determine rates of complications and opioid use. Complications were classified 30 days after RP using the Clavien-Dindo system. Patient characteristics and outcomes were compared using appropriate statistical tests. Logistic and linear regressions were performed to identify predictors of complications and evaluate the relationship between complications and postoperative opioid use. RESULTS: A total of 124 (24.8%) men underwent ORP and 376 (75.2%) RARP, with 418 (83.6%) receiving pelvic lymph node dissection (PLND). While 83 patients (16.6%) had complications, only 19 (3.8%) were major (Clavien-Dindo Grade ≥III), with no differences by surgical approach. PLND (odds ratio [OR] 2.96, 95% confidence interval [CI] 1.25-8.71; P = 0.03) and Stage pT3b (OR 2.76, 95% CI 1.23-6.00;P = 0.01) were the only predictors of complications after controlling for potential confounders. Patients who had complications had greater inpatient (P = 0.02) and outpatient (P = 0.005) opioid use, which persisted after controlling for patient-reported pain, attending surgeon variation, surgical approach, and undergoing PLND (inpatient β:77.2, 95% CI 17.9-136.5,P = 0.03; and outpatient β:21.9, 95% CI 4.7-39.1,P = 0.01). CONCLUSION: In an analysis of prospectively collected data, overall and major complications rates did not differ by surgical approach. Patients receiving PLND and with Stage pT3b disease had more complications. Complications were independently associated with higher inpatient and outpatient postoperative opioid use.
引用
- Huang MM, Su ZT, Becker REN, et al. Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial. BJU Int. 2020. PMID: 32654363. doi:10.1111/bju.15172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。